Tag
This article reviews a multicenter study comparing outcomes of different treatment approaches for gastric cancer patients with positive peritoneal cytology (CY1) and/or localized peritoneal metastasis (P1a), highlighting the superior surviv
In the four-arm SleepCARE trial of 219 women receiving breast cancer chemotherapy, brief CBT-I significantly improved insomnia while bright light therapy did not beat sleep hygiene education. Neither helped fatigue, and combining the two added burden without benefit.
A multicenter German registry study comparing carboplatin/paclitaxel to other chemotherapy regimens in anaplastic thyroid cancer found no survival advantage, highlighting the importance of molecular diagnostics and multimodal treatment appr
This review analyzes the impact of age and anthracycline-based chemotherapy on mortality in 28,000 classic Hodgkin lymphoma patients, highlighting poorer outcomes in the elderly and the therapeutic nuances influencing survival.
This phase 2 trial compares CPX-351 with CLAG-M chemotherapy in medically unfit adults with AML, finding CLAG-M achieves better 3-month survival and response rates, especially in patients with proliferative disease, suggesting intensive the
This international cohort study evaluates the effectiveness of CHOEP/EPOCH versus CHOP chemotherapy in aggressive adult T-cell leukemia/lymphoma, revealing subtype-specific survival benefits in lymphomatous ATL but inconclusive results in a
Five-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.
This multicenter study reveals that total-body irradiation (TBI) conditioning before hematopoietic stem cell transplantation severely compromises pregnancy outcomes compared to alkylating agents or conventional chemotherapy in female surviv
Over 25% of endometrial cancer patients receiving chemotherapy develop venous thromboembolism, with advanced cancer stage as the key risk factor, highlighting the need for tailored risk assessment and preventive strategies.
A Medicare-based study found the Oncology Care Model did not increase systemic therapy starts for newly diagnosed cancer and was linked to less treatment initiation and lower spending in poor-prognosis cancer.
This Phase II trial evaluates first-line anlotinib plus anthracyclines and ifosfamide followed by anlotinib maintenance for advanced soft-tissue sarcoma, showing an objective response rate of 30.8% and a manageable safety profile, suggestin
The CITRINE trial demonstrates that adding adjuvant carboplatin to standard chemotherapy significantly improves survival in high-risk triple-negative breast cancer patients, primarily by preventing early recurrence.
A CCSS analysis of 25,723 five-year childhood cancer survivors shows clear dose-response relationships between colorectum-specific radiation dose, irradiated colorectal volume, several chemotherapy exposures (notably procarbazine, high alky
This meta-analysis reveals that systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, with greater benefits in younger men and nuanced effects in older men, especially based on disease
Immune-checkpoint inhibitors combined with chemotherapy have redefined treatment for advanced biliary tract cancer, offering improved survival despite challenges posed by tumor heterogeneity and biomarker limitations. Ongoing research explo
This article reviews the latest evidence demonstrating improved overall survival with osimertinib combined with chemotherapy in first-line treatment of EGFR-mutated advanced non-small-cell lung cancer.
This article reviews the phase 3 POD1UM-304 trial demonstrating that adding retifanlimab to platinum-based chemotherapy improves overall survival in first-line metastatic NSCLC, highlighting its potential as a new standard of care.
The POD1UM-304 study demonstrated that adding the PD-1 inhibitor retifanlimab to platinum-based chemotherapy significantly improves overall survival in patients with first-line metastatic non-small-cell lung cancer, offering a new therapeut
The Evolution trial evaluated pembrolizumab combined with chemotherapy without radiotherapy in unresectable, locally advanced NSCLC patients with PD-L1 TPS ≥50%, showing a 2-year progression-free survival rate of 67% and manageable safety p
A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.
